New registry aims to unlock why BRCA mutations lead to pancreatic cancer
NCT ID NCT01983410
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study creates a registry for people with BRCA or PALB2 gene mutations who have pancreatic cancer, along with their close relatives. Researchers will collect medical information, blood samples, and tumor tissue to better understand why pancreatic cancer develops in this group. No treatments are tested; the goal is to gather data for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this registry could help researchers understand why some people with BRCA mutations develop pancreatic cancer, potentially pointing toward better screening or prevention strategies.
What could go wrong
This is an observational registry, not a treatment trial. It collects information and samples but does not test any intervention, so it cannot directly lead to a cure or therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, 19104-4283, United States
-
Cold Springs Harbor Laboratory (Specimen Analysis)
Cold Spring Harbor, New York, 11724, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Shaare Zedek Medical Center
Jerusalem, Israel
-
Sheba Medical Center
Tel Litwinsky, Israel
-
Weill Cornell Medical College (Specimen Analysis)
New York, New York, United States
-
Weizmann Institute of Science (Specimen Analysis)
Rehovot, Israel